Skip to main content
. 2012 Oct 25;1(1):65–70. doi: 10.3892/br.2012.28

Figure 2.

Figure 2.

Effects of irbesartan, GW9662 and hepatocyte growth factor neutralizing antibody (HGF-Ab) on F4/80 staining and adipocyte diameter in adipose tissue. (A) Typical micrographs of immunostaining for F4/80 in periodic cross-sections of epididymal adipose tissue after 12 weeks of high-fat diet (HFD). Brown-stained area shows F4/80 protein-positive area; (a) control (HFD only), (b) HFD + irbesartan (5 mg/kg/day), (c) HFD + irbesartan + GW9662, a PPARγ antagonist (0.5 mg/kg/day) and (d) HFD + irbesartan + neutralizing antibody against HGF (200 μg/week); bar, 100 μm. (B) Adipocyte diameter (μm). (C) Quantitative data of immunohistochemical staining for macrophages (F4/80) (%). Control, HFD only; (−), HFD + irbesartan (5 mg/kg/day); GW9662, HFD + irbesartan + GW9662, a PPARγ antagonist (0.5 mg/kg/day); HGF-Ab, HFD + irbesartan + neutralizing antibody against HGF (200 μg/week). *P<0.01 vs. control, †P<0.05 vs. irbesartan only. Data are shown as the mean ± standard error of the mean. PPARγ; peroxisome proliferators activated receptor-γ.